Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay

European Journal of Cancer

Volumn 32, Issue 5, 1996, Pages 793-801

  Ferno M ^a   Bendahl, P O ^a   Borg, A ^a   Brundell, J ^b   Hirschberg, L ^b   Olsson, H ^a   Killander, D ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b AB Sangtec Medical   (Sweden)

Author keywords

Breast cancer; Luminometric immunoassay; Prognosis; Urokinase plasminogen activator

Indexed keywords

UROKINASE;

ADULT; AGED; ARTICLE; ASSAY; BREAST CANCER; CONTROLLED STUDY; CYTOSOL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOSOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOASSAY; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029950191     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00652-4     Document Type: Article

References (31)

1. Blood CH, Zetter BR. Tumor interaction with the vasculature; angiogenesis and tumour metastasis. Biochem Biophys Acta 1990, 1032, 89-118.
2. Steeg PS. Invasion and metastasis. Curr Opin Oncol 1992, 4, 134-141.
3. Pöllänen J, Stephens R, Salonen EM, Vaheri A. Proteolytic mechanisms operating at the surface of invasive cells. Adv Exp Med Biol 1988, 233, 187-199.
4. Danö K, Andreasen PA, Gröndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985, 44, 139-226.
5. Âstedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 1976, 261.
6. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988, 62, 531-533.
7. Duffy MJ, Reilly D, O'Sullivan C, Fenely JJ, Andreasen P. Urokinase-plasminogen activator, a new independent prognostic marker in breast cancer. Cancer Res 1990, 50, 6827-6829.
8. Jänicke F, Schmitt M, Hafter R, et al. Urokinase-type plasminogen activator (uPA) antigen is a predictor for early relapse in breast cancer. Fibrinolysis 1990, 4, 69-78.
9. Foekens JA, Schmitt M, van Putten WLJ, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992, 52, 6101-6105.
10. Foekens JA, Schmitt M, van Putten WL, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994, 12, 1648-1658.
11. Gröndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1992, 53, 2513-2521.
12. Spyratos F, Martin P-M, Hacène K, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992, 84, 1266-1272.
13. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1995, 69, 398-405.
14. Sigurdsson H, Baldetorp B, Borg Å, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990, 322, 1045-1053.
15. Lowry OH, Roseborough N, Farr L, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193, 265-275.
16. Norgren A, Borg Å, Fernö M, Johansson U, Lindahl B, Tsiobanelis K. Improved method for assay of estradiol and progesterone receptors with special reference to breast cancer. Anticancer Res 1982, 2, 315-320.
17. Baldetorp B, Dahlberg M, Holst U, Lindgren G. Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm. Cytometry 1989, 10, 695-705.
18. Hiddemann W, Schumann J, Andreeff M, et al. Convention on nomenclature for DNA cytometry. Cytometry 1984, 5, 445-446.
19. Baisch H, Gohde W, Linden WA. Analysis of PCP-data to determine the fraction of cells in various phases of cell cycle. Rad Environ Biophys 1975, 12, 31-39.
20. Fernö M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D. Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncol 1992, 31, 157-165.
21. Borg Å, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990, 50, 4332-4337.
22. Borg A, Lennerstrand J, Fernö M, Killander D, Lane D, Brundell J. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable in steroid receptor cytosols. Br J Cancer 1995, 71, 1013-1017.
23. Fernö M, Baldetorp B, Borg Å, et al. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 1994, 30A, 2042-2048.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
25. Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50, 163-170.
26. Altman DG. Practical Statistics for Medical Research. Chapman & Hall, London, 1991, 386.
27. Cox DR. Regression models and life-tables. J R Stat Soc (B) 1972, 34, 187-220.
28. Schoenfeld D. Chi-squared goodness-of-fit test for the proportional hazard regression model. Biometrika 1980, 67, 145-153.
29. Yamashita J, Ogawa M, Sakai K. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 1995, 117, 601-608.
30. Rosenquist C, Thorpe SM, Danö K, Gröndahl-Hansen J. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat 1993, 28, 223-229.
31. Jänicke F, Pache L, Schmitt M, et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator type 1. Cancer Res 1994, 54, 2527-2530.